Header image
LinkedIn
Facebook

Latest News

Multi-million Euro research initiative undertakes ...

Transforming Crohn’s Disease

At INTERCEPT, we are transforming the landscape of Crohn’s disease research by shifting from reactive symptom management to proactive early detection and prevention by using biomarkers to identify individuals at risk before symptoms develop, making diagnosis earlier than early.

Learn More

Prof Dr Geert D’Haens

“INTERCEPT has a unique and highly international character bringing together bright scientists from across the European continent, North America and South Korea. This creates numerous opportunities and the potential to lead to the most significant scientific progress in the field since the initial description of the disease by Burrill Crohn himself in 1932.”
INTERCEPT Project Coordinator
Stichting Amsterdam UMC (AUMC)

Prof Jean-Frédéric Colombel

“For the first time, researchers from multiple European countries, North America and South Korea are working together to predict and prevent Crohn’s Disease, reaching a milestone in the long path we began to walk many years ago. Our combined success would reinforce the concept that immune-mediated diseases that not only affect the gut but also the joints, the skin and the brain can be prevented.”
Co-lead PI for INTERCEPT
Icahn School of Medicine at Mount Sinai in New York

Dr. Pratik Panchal

“At Takeda, we are committed to improving outcomes for people living with Crohn’s disease and have been working together with leaders across the IBD landscape for more than thirty-five years towards this goal. We know that addressing the complexities of Crohn’s disease is only possible through deep engagement of the industry with the broader scientific community, and our partnership with the Innovative Health Initiative reflects this. Our great hope is that the INTERCEPT Project helps to develop and deploy a biomarker panel that ultimately enables effective and early diagnosis and treatment of Crohn’s disease, even before symptoms begin, thus changing the course of disease and lessening the immense burden of this chronic illness on patients and their loved ones.”
Medical Director & Head of Inflammatory Bowel Disease Product Science, Gastrointestinal and Inflammation Therapeutic Area
Takeda

Families at the centre

Families are at the heart of our research and our aim to pioneer a future without Crohn’s disease, impacting and improving the lives of generations to come. The INTERCEPT project aims to verify and clinically validate a panel of biomarkers and build a blood risk score that can identify individuals with a high risk of developing Crohn’s disease within five years after initial evaluation. Find out more about our study and how you can be a part of it.

Learn More

Contact us

If you are a researcher, industry representative, a first-degree relative of a person living with Crohn’s disease or interested in knowing more about our research and clinical trials, please feel free to reach out to us.

Contact us

START
01 JANUARY 2025
DURATION
60 MONTHS
BUDGET
€ 38.05 Mio
TEAM
21 Partners from 16 Countries